How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease

References

• Steinberg D. The cholesterol controversy is over. Why did it take so long? Circulation 1989;80:1070-8
   PubMed Web of Science ®Google Scholar
• Steinberg D. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. J Lipid Res 2013;54:2946-9
   PubMed Web of Science ®Google Scholar
• Pinckney ER, Pinckney C. The Cholesterol Controversy. Sherbourne Press; Los Angeles: 1975
   Google Scholar
• Smith RL. The Cholesterol Conspiracy. Warren H. Green; St. Louis, Missoury: 1991
   Google Scholar
• Ravnskov U. An elevated serum cholesterol level is secondary, not causal, in coronary heart disease. Med Hypotheses 1991;36:238-41
   Google Scholar
• Berger M. The cholesterol non-consensus. Methodological difficulties in the interpretation of epidemiological studies. Bibl Nutr Dieta 1992;49:125-30
   Google Scholar
• Gurr ML. Dietary lipids and coronary heart disease: old evidence, new perspective. Prog Lipid Res 1992;31:195-243
   PubMed Web of Science ®Google Scholar
• Ravnskov U. A hypothesis out-of-date: the diet-heart idea. J Clin Epidemiol 2002;55:1057-63
   PubMed Web of Science ®Google Scholar
• Grimes DS. An epidemic of coronary heart disease. QJM 2012;105:509-18
   Google Scholar
• Marshall TM. New insights into the statin-cholesterol controversy. J Am Phys Surg 2014;19:42-6
   Google Scholar
• Lande KE, Sperry WM. Human atherosclerosis in relation to cholesterol content of blood serum. Arch Pathol 1936;22:301-13
   Google Scholar
• Ravnskov U. Is atherosclerosis caused by high cholesterol? QJM 2002;95:397-403
   PubMed Web of Science ®Google Scholar
• Rosch PJ. Cholesterol does not cause coronary heart disease in contrast to stress. Scand Cardiovasc J 2008;42:244-9
   PubMed Web of Science ®Google Scholar
• Schersten T, Rosch PJ, Arfors KE, et al. The cholesterol hypothesis: time for the obituary? Scand Cardiovasc J 2011;45:322-3
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 2014;129(25 Suppl 2):S1-45
   PubMed Web of Science ®Google Scholar
• Roberts WC. The underused miracle drugs: the statin drugs are to atherosclerosis what penicillin was to infectious disease. Am J Cardiol 1996;78:377-8
   Web of Science ®Google Scholar
• Jeger R, Dieterle T. Statins: have we found the Holy Grail? Swiss Med Weekly 2012;142:w13515
   Google Scholar
• Oliver M, Poole-Wilson P, Shepherd J, et al. Lower patients’ cholesterol now. BMJ 1995;310:1280-1
   Google Scholar
• Lindholm LH, Samuelsson O. What are the odds at ASCOT today? Lancet 2003;361:1144-5
   Google Scholar
• Thompson A, Temple NJ. The case for statins: has it really been made? J R Soc Med 2004;97:461-4
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
   PubMed Web of Science ®Google Scholar
• Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3
   PubMed Web of Science ®Google Scholar
• Foody J. Statin use associated with increased risk of cataract, myopathy, liver dysfunction and acute renal failure with varying numbers needed to harm. Evid Based Med 2010;15:187-8
   Google Scholar
• Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci 2012;89:1165-71
   PubMed Web of Science ®Google Scholar
• Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol 2011;22:460-6
   PubMed Web of Science ®Google Scholar
• Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800-11
   PubMed Web of Science ®Google Scholar
• Goldstein MR, Mascitelli L. Do statins decrease cardiovascular disease at the expense of increasing cancer? Int J Cardiol 2009;133:254-5
   Google Scholar
• McDougall JA, Malone KE, Daling JR, et al. Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age. Cancer Epidemiol Biomarkers Prev 2013;22:1529-37
   PubMedGoogle Scholar
• Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996;335:1001-9
   PubMed Web of Science ®Google Scholar
• Ravnskov U, McCully KM. Vulnerable plaque formation from obstruction of vasa vasorum by homocysteinylated and oxidized lipoprotein aggregates complexed with microbial remnants and LDL autoantibodies. Ann Clin Lab Sci 2009;39:3-16
   PubMed Web of Science ®Google Scholar
• Read SA, Douglas MW. Virus induced inflammation and cancer development. Cancer Lett 2014;345:174-81
   Google Scholar
• Chen Z, Keech A, Collins R, et al. Prolonged infection with hepatitis B virus and association between low blood cholesterol concentration and liver cancer. BMJ 1993;306:890-4
   Google Scholar
• Ravnskov U, Rosch PJ, McCully KS. The statin-low cholesterol-cancer conundrum. QJM 2012;105:383-8
   PubMed Web of Science ®Google Scholar
• Dayton S, Pearce ML, Hashimoto S, et al. A controlled clinical trial of a diet high in un­saturated fat in preventing complications of atherosclerosis. Circulation 1969;40(suppl II):1-63
   Google Scholar
• Oliver MF. Cholesterol-lowering and cancer in the prevention of cardiovascular disease. QJM 2010;103:202
   Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56
   PubMed Web of Science ®Google Scholar
• Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-2
   PubMedGoogle Scholar
• Golomb BA. Statins and activity: proceed with caution. JAMA Intern Med 2014;174:1270-2
   Google Scholar
• Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol 2002;40:163-71
   PubMed Web of Science ®Google Scholar
• Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525-8
   PubMed Web of Science ®Google Scholar
• Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5
   PubMed Web of Science ®Google Scholar
• Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94-102
   PubMed Web of Science ®Google Scholar
• Muldoon MF, Manuck SB, Matthew HA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14
   PubMed Web of Science ®Google Scholar
• Boston PF, Dursun SM, Reveley MA. Cholesterol and mental disorder. Br J Psychiatry 1996;169:682-9
   PubMed Web of Science ®Google Scholar
• Asellus P, Nordström P, Nordström AL, et al. Cholesterol and the “Cycle of Violence” in attempted suicide. Psychiatry Res 2014;215:646-50
   Google Scholar
• Kaplan JR, Muldoon MF, Manuck SB, et al. Assessing the observed relationship between low cholesterol and violence-related mortality. Implications for suicide risk. Ann N Y Acad Sci 1997;836:57-80
   PubMed Web of Science ®Google Scholar
• Horrobin D. Personal view. Lowered cholesterol concentrations and mortality. BMJ 1990;301:55
   Google Scholar
• Agargün MY, Algün E, Sekeroğlu R. Low cholesterol level in patients with panic disorder: the association with major depression. J Affect Disord 1998;50:29-32
   Google Scholar
• Kim JM, Stewart R, Shin IS, et al. Low cholesterol, cognitive function and Alzheimer s disease in a community population with cognitive impairment. J Nutr Health Aging 2002;6:320-3
   PubMedGoogle Scholar
• Ozer OA, Kutaniş R, Agargun MY. Serum lipid levels, suicidality, and panic disorder. Compr Psych 2004;45:95-8
   PubMed Web of Science ®Google Scholar
• Vilibić M, Jukić V, Pandžić-Sakoman M, et al. Association between total serum cholesterol and depression, aggression, and suicidal ideations in war veterans with posttraumatic stress disorder: a cross-sectional study. Croat Med J 2014;55:520-9
   PubMed Web of Science ®Google Scholar
• Davison KM, Kaplan BJ. Lipophilic statin use and suicidal ideation in a sample of adults with mood disorders. Crisis 2014;35:278-82
   PubMedGoogle Scholar
• Kim YK, Lee HJ, Kim JY, et al. Low serum cholesterol is correlated to suicidality in a Korean sample. Acta Psychiatr Scand 2002;105:141-8
   PubMed Web of Science ®Google Scholar
• Hoyer S, Riederer P. Alzheimer disease—no target for statin treatment. Neurochem Res 2007;32:695-706
   PubMedGoogle Scholar
• Padala KP, Padala PR, McNeilly DP, et al. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012;10:296-302
   PubMedGoogle Scholar
• Sahebzamani FM, Munro CL, Marroquin OC, et al. Examination of the FDA warning for statins and cognitive dysfunction. J Pharmacovigil 2014;2:4-12
   Google Scholar
• Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case-control study. Neurology 2002;58:1333-7
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90
   PubMed Web of Science ®Google Scholar
• Sultan S, Hynes N. The ugly side of statins. Systemic appraisal of the contemporary un-known unknowns. OJ Endocr Metab Dis 2013;3:10.4236/ojemd.2013.33025
   Google Scholar
• Spence D. Bad medicine: statins. BMJ 2013;346:f3566
   Google Scholar
• McCartney M. Medicine and the media. Statins for all? BMJ 2012;345:e6044
   Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. American college of cardiology/American heart association task force on practice guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;6(25 Pt B):2889-934
   Google Scholar
• Lenzer J. Majority of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers. BMJ 2013;347:f6989
   Google Scholar
• Angell M. The truth about the drug companies: How they deceive us and what to do about it. Random House; NY: 2004
   Google Scholar
• Gøtzsche P. Deadly medicines and organised crime: How big pharma has corrupted healthcare. Radcliff Publishing Ltd; London: 2013
   Google Scholar
• Chew M, Brizzel C, Abbasi K, et al. Medical journals and industry ties. BMJ 2014;349:g7197
   PubMedGoogle Scholar
• de Ferranti S, Ludwig DS. Storm over statins–the controversy surrounding pharmacologic treatment of children. N Engl J Med 2008;359:1309-12
   PubMed Web of Science ®Google Scholar
• Volek JS, Fernandez ML, Feinman RD, et al. Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res 2008;47:307-18
   PubMed Web of Science ®Google Scholar
• Dashti HM, Mathew TC, Khadada M, et al. Beneficial effects of ketogenic diet in obese diabetic subjects. Mol Cell Biochem 2007;302:249-56
   Google Scholar
• Feinman RD, Pogozelski WK, Astrup A, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition 2015;31:1-13
   PubMed Web of Science ®Google Scholar
• Kummerow FA. The negative effects of hydrogenated trans fats and what to do about them. Atherosclerosis 2009;205:458-65
   PubMed Web of Science ®Google Scholar
• Bendsen NT, Christensen R, Bartels EM, et al. Consumption of industrial and ruminant trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort studies. Eur J Clin Nutr 2011;65:773-83
   PubMed Web of Science ®Google Scholar
• Feinman RD. Saturated fat and health: recent advances in research. Lipids 2010;45(10):891-2
   Google Scholar
• Siri-Tarino PW, Sun Q, Hu FB, et al. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr 2010;91:502-9
   PubMed Web of Science ®Google Scholar
• Ravnskov U, Diamond D, Karatay MC, et al. No scientific support for linking dietary saturated fat to CHD. Br J Nutr 2012;107:455-7
   Google Scholar
• Ravnskov U, Dinicolantonio JJ, Harcombe Z, et al. The questionable benefits of exchanging saturated fat with polyunsaturated fat. Mayo Clin Proc 2014;89:451-3
   PubMed Web of Science ®Google Scholar